Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

NCT07219121 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Proteinuria
Immunoglobulin A (IgA) Nephropathy
Focal Segmental Glomerulosclerosis
Kidney Transplant

Interventions

DRUG: Sparsentan

Sponsor

Travere Therapeutics, Inc.